ZIOPHARMA Oncology Inc. Analyst Coverage Initiated: Brief Report Issued by BrokerBank Securities, Inc.

NEW YORK, Feb. 17, 2015 /PRNewswire/ -- ZIOPHARMA Oncology Inc. ZIOP a biotechnology company, engaged in the discovery and development of cancer therapies based in Boston, MA  was one of the most traded companies today on the NASDAQ. ZIOP reached a new 52 week high and closed at nearly $10/share, up from a 52 week low of $2.31 in October of 2014.

The company is still a new pharmaceutical with a pipeline of products in or entering clinical studies. Thus far, the share price has been news driven and has seen substantial appreciation over the past four months. News is expected to continue as the company believes it may start clinical trials of five new products. What the share price does is difficult to predict, but some indicators may hold the key to understanding the upcoming trends.

For a more detailed research report with analyst comments and recommendation on ZIOPHARMA Oncology Inc. please follow the link. There is no cost obligation required to view analyst brief:

http://bit.ly/-ZIOP-AnalystReport

Copy and paste to browser may be required.

Forward-Looking Disclaimer   
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.

CFA^® and Chartered Financial Analyst^® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ziopharma-oncology-inc-analyst-coverage-initiated-brief-report-issued-by-brokerbank-securities-inc-300036483.html

SOURCE BrokerBank Securities, Inc.